Roflumilast ameliorates airway hyperresponsiveness caused by diet-induced obesity in a murine model

Hye Jung Park, Jae Hyun Lee, Yoon Hee Park, Heejae Han, Da Woon Sim, Kyung Hee Park, Jungwon Park

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Obese patients with asthma respond poorly to conventional asthma medications, resulting in severe symptoms and poor prognosis. Roflumilast, a phosphodiesterase-4 inhibitor that lowers the levels of various substances that are implicated in obese subjects with asthma, may be effective in the treatment of those subjects. We evaluated the potential of roflumilast as a novel therapeutic agent for obese subjects with asthma. We designed three models: diet-induced obesity (DIO); DIO with ovalbumin (OVA); and OVA. We fed C57BL/6J mice a high-fat diet for 3 months with or without OVA sensitization and challenge. Roflumilast or dexamethasone was administered orally three times at 2-day intervals in the last experimental week. Airway hyperresponsiveness resulting from DIO significantly improved in the roflumilast-treated group compared with the dexamethasonetreated groups. Although DIO did not affect the cell proliferation in bronchoalveolar lavage fluid, increased fibrosis was seen in the DIO group, which significantly improved from treatment with roflumilast. DIO-induced changes in adiponectin and leptin levels were improved by roflumilast, whereas dexamethasone aggravated them. mRNA levels and proteins of TNF-a, transforming growth factor-b, IL-1b, and IFN-g increased in the DIO group and decreased with roflumilast. The reactive oxygen species levels were also increased in the DIO group and decreased by roflumilast. In the DIO plus OVA and OVA models, roflumilast improved Th1 and Th2 cell activation to a greater extent than dexamethasone. Roflumilast is significantly more effective than dexamethasone against airway hyperresponsiveness caused by DIO in the murine model. Roflumilast may represent a promising therapeutic agent for the treatment of obese patients with asthma.

Original languageEnglish
Pages (from-to)82-91
Number of pages10
JournalAmerican Journal of Respiratory Cell and Molecular Biology
Volume55
Issue number1
DOIs
Publication statusPublished - 2016 Jul 1

Fingerprint

Nutrition
Obesity
Diet
Ovalbumin
Asthma
Dexamethasone
Roflumilast
Phosphodiesterase 4 Inhibitors
Therapeutics
Th2 Cells
Th1 Cells
Adiponectin
Bronchoalveolar Lavage Fluid
Cell proliferation
Transforming Growth Factors
High Fat Diet
Leptin
Inbred C57BL Mouse
Reactive Oxygen Species
Fibrosis

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Pulmonary and Respiratory Medicine
  • Clinical Biochemistry
  • Cell Biology

Cite this

Park, Hye Jung ; Lee, Jae Hyun ; Park, Yoon Hee ; Han, Heejae ; Sim, Da Woon ; Park, Kyung Hee ; Park, Jungwon. / Roflumilast ameliorates airway hyperresponsiveness caused by diet-induced obesity in a murine model. In: American Journal of Respiratory Cell and Molecular Biology. 2016 ; Vol. 55, No. 1. pp. 82-91.
@article{98a9c4aca5af4d7491d4e4c5c862323a,
title = "Roflumilast ameliorates airway hyperresponsiveness caused by diet-induced obesity in a murine model",
abstract = "Obese patients with asthma respond poorly to conventional asthma medications, resulting in severe symptoms and poor prognosis. Roflumilast, a phosphodiesterase-4 inhibitor that lowers the levels of various substances that are implicated in obese subjects with asthma, may be effective in the treatment of those subjects. We evaluated the potential of roflumilast as a novel therapeutic agent for obese subjects with asthma. We designed three models: diet-induced obesity (DIO); DIO with ovalbumin (OVA); and OVA. We fed C57BL/6J mice a high-fat diet for 3 months with or without OVA sensitization and challenge. Roflumilast or dexamethasone was administered orally three times at 2-day intervals in the last experimental week. Airway hyperresponsiveness resulting from DIO significantly improved in the roflumilast-treated group compared with the dexamethasonetreated groups. Although DIO did not affect the cell proliferation in bronchoalveolar lavage fluid, increased fibrosis was seen in the DIO group, which significantly improved from treatment with roflumilast. DIO-induced changes in adiponectin and leptin levels were improved by roflumilast, whereas dexamethasone aggravated them. mRNA levels and proteins of TNF-a, transforming growth factor-b, IL-1b, and IFN-g increased in the DIO group and decreased with roflumilast. The reactive oxygen species levels were also increased in the DIO group and decreased by roflumilast. In the DIO plus OVA and OVA models, roflumilast improved Th1 and Th2 cell activation to a greater extent than dexamethasone. Roflumilast is significantly more effective than dexamethasone against airway hyperresponsiveness caused by DIO in the murine model. Roflumilast may represent a promising therapeutic agent for the treatment of obese patients with asthma.",
author = "Park, {Hye Jung} and Lee, {Jae Hyun} and Park, {Yoon Hee} and Heejae Han and Sim, {Da Woon} and Park, {Kyung Hee} and Jungwon Park",
year = "2016",
month = "7",
day = "1",
doi = "10.1165/rcmb.2015-0345OC",
language = "English",
volume = "55",
pages = "82--91",
journal = "American Journal of Respiratory Cell and Molecular Biology",
issn = "1044-1549",
publisher = "American Thoracic Society",
number = "1",

}

Roflumilast ameliorates airway hyperresponsiveness caused by diet-induced obesity in a murine model. / Park, Hye Jung; Lee, Jae Hyun; Park, Yoon Hee; Han, Heejae; Sim, Da Woon; Park, Kyung Hee; Park, Jungwon.

In: American Journal of Respiratory Cell and Molecular Biology, Vol. 55, No. 1, 01.07.2016, p. 82-91.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Roflumilast ameliorates airway hyperresponsiveness caused by diet-induced obesity in a murine model

AU - Park, Hye Jung

AU - Lee, Jae Hyun

AU - Park, Yoon Hee

AU - Han, Heejae

AU - Sim, Da Woon

AU - Park, Kyung Hee

AU - Park, Jungwon

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Obese patients with asthma respond poorly to conventional asthma medications, resulting in severe symptoms and poor prognosis. Roflumilast, a phosphodiesterase-4 inhibitor that lowers the levels of various substances that are implicated in obese subjects with asthma, may be effective in the treatment of those subjects. We evaluated the potential of roflumilast as a novel therapeutic agent for obese subjects with asthma. We designed three models: diet-induced obesity (DIO); DIO with ovalbumin (OVA); and OVA. We fed C57BL/6J mice a high-fat diet for 3 months with or without OVA sensitization and challenge. Roflumilast or dexamethasone was administered orally three times at 2-day intervals in the last experimental week. Airway hyperresponsiveness resulting from DIO significantly improved in the roflumilast-treated group compared with the dexamethasonetreated groups. Although DIO did not affect the cell proliferation in bronchoalveolar lavage fluid, increased fibrosis was seen in the DIO group, which significantly improved from treatment with roflumilast. DIO-induced changes in adiponectin and leptin levels were improved by roflumilast, whereas dexamethasone aggravated them. mRNA levels and proteins of TNF-a, transforming growth factor-b, IL-1b, and IFN-g increased in the DIO group and decreased with roflumilast. The reactive oxygen species levels were also increased in the DIO group and decreased by roflumilast. In the DIO plus OVA and OVA models, roflumilast improved Th1 and Th2 cell activation to a greater extent than dexamethasone. Roflumilast is significantly more effective than dexamethasone against airway hyperresponsiveness caused by DIO in the murine model. Roflumilast may represent a promising therapeutic agent for the treatment of obese patients with asthma.

AB - Obese patients with asthma respond poorly to conventional asthma medications, resulting in severe symptoms and poor prognosis. Roflumilast, a phosphodiesterase-4 inhibitor that lowers the levels of various substances that are implicated in obese subjects with asthma, may be effective in the treatment of those subjects. We evaluated the potential of roflumilast as a novel therapeutic agent for obese subjects with asthma. We designed three models: diet-induced obesity (DIO); DIO with ovalbumin (OVA); and OVA. We fed C57BL/6J mice a high-fat diet for 3 months with or without OVA sensitization and challenge. Roflumilast or dexamethasone was administered orally three times at 2-day intervals in the last experimental week. Airway hyperresponsiveness resulting from DIO significantly improved in the roflumilast-treated group compared with the dexamethasonetreated groups. Although DIO did not affect the cell proliferation in bronchoalveolar lavage fluid, increased fibrosis was seen in the DIO group, which significantly improved from treatment with roflumilast. DIO-induced changes in adiponectin and leptin levels were improved by roflumilast, whereas dexamethasone aggravated them. mRNA levels and proteins of TNF-a, transforming growth factor-b, IL-1b, and IFN-g increased in the DIO group and decreased with roflumilast. The reactive oxygen species levels were also increased in the DIO group and decreased by roflumilast. In the DIO plus OVA and OVA models, roflumilast improved Th1 and Th2 cell activation to a greater extent than dexamethasone. Roflumilast is significantly more effective than dexamethasone against airway hyperresponsiveness caused by DIO in the murine model. Roflumilast may represent a promising therapeutic agent for the treatment of obese patients with asthma.

UR - http://www.scopus.com/inward/record.url?scp=84988924403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988924403&partnerID=8YFLogxK

U2 - 10.1165/rcmb.2015-0345OC

DO - 10.1165/rcmb.2015-0345OC

M3 - Article

C2 - 26756251

AN - SCOPUS:84988924403

VL - 55

SP - 82

EP - 91

JO - American Journal of Respiratory Cell and Molecular Biology

JF - American Journal of Respiratory Cell and Molecular Biology

SN - 1044-1549

IS - 1

ER -